Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study.

However, findings did not reach statistical significance in this smaller cohort, and all the oral and intravenous DMDs were grouped together due to their lower uptake at that time. 13 Our current study advanced these findings considerably by accessing more contemporary data and a much larger MS population (n = 19,360) with a longer follow-up period. 13 A

also in 111,027 other papers